Sibeprenlimab Reference: HY-P99901 Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody. Sibeprenlimab can inhibit APRIL. Sibeprenlimab can be used for the research of IgA nephropathy (IgAN).
Trial Kit containing: CD9 Clone CGS12A, CD63 Clone CGS82X and CD81 Clone CGS36K Reference: EX205 All high-quality exosome validated antibodies have been selected to specifically detect CD9, CD63, and/or CD81 which are widely used as exosome markers. The antibodies can be selected individually or as part of a convenient and economical collection containing 20 µg of each of the following antibodies: CD9 Clone CGS12A, CD63 Clone CGS82X, and CD81 Clone CGS36K.
Tengonermin Reference: HY-P99565 Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment.
Tinurilimab Reference: HY-P99051 Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors.
Ralpancizumab Reference: HY-P99816 Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke.
Glenzocimab Reference: HY-P99644 Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke.
Pepinemab Reference: HY-P99407 Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D.